These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9242457

  • 1. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.
    Nehmé A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, Wang JY, Howell SB, Christen RD.
    Cancer Res; 1997 Aug 01; 57(15):3253-7. PubMed ID: 9242457
    [Abstract] [Full Text] [Related]

  • 2. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
    Nehmé A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD.
    Br J Cancer; 1999 Mar 01; 79(7-8):1104-10. PubMed ID: 10098743
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
    Persons DL, Yazlovitskaya EM, Cui W, Pelling JC.
    Clin Cancer Res; 1999 May 01; 5(5):1007-14. PubMed ID: 10353733
    [Abstract] [Full Text] [Related]

  • 4. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
    Okumura K, Shirasawa S, Nishioka M, Sasazuki T.
    Cancer Res; 1999 May 15; 59(10):2445-50. PubMed ID: 10344756
    [Abstract] [Full Text] [Related]

  • 5. Determination of cell fate by c-Abl activation in the response to DNA damage.
    Kharbanda S, Yuan ZM, Weichselbaum R, Kufe D.
    Oncogene; 1998 Dec 24; 17(25):3309-18. PubMed ID: 9916993
    [Abstract] [Full Text] [Related]

  • 6. c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation.
    Cong F, Goff SP.
    Proc Natl Acad Sci U S A; 1999 Nov 23; 96(24):13819-24. PubMed ID: 10570156
    [Abstract] [Full Text] [Related]

  • 7. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.
    Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D.
    J Biol Chem; 1997 May 30; 272(22):14041-4. PubMed ID: 9162025
    [Abstract] [Full Text] [Related]

  • 8. Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells.
    Helbig L, Damrot J, Hülsenbeck J, Köberle B, Brozovic A, Osmak M, Fiket Z, Kaina B, Fritz G.
    J Biol Chem; 2011 Apr 15; 286(15):12991-3001. PubMed ID: 21324906
    [Abstract] [Full Text] [Related]

  • 9. Lack of c-Jun activity increases survival to cisplatin.
    Sánchez-Pérez I, Perona R.
    FEBS Lett; 1999 Jun 18; 453(1-2):151-8. PubMed ID: 10403393
    [Abstract] [Full Text] [Related]

  • 10. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
    Raitano AB, Halpern JR, Hambuch TM, Sawyers CL.
    Proc Natl Acad Sci U S A; 1995 Dec 05; 92(25):11746-50. PubMed ID: 8524841
    [Abstract] [Full Text] [Related]

  • 11. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents.
    Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, Kufe DW.
    Nature; 1995 Aug 31; 376(6543):785-8. PubMed ID: 7651539
    [Abstract] [Full Text] [Related]

  • 12. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage.
    Kharbanda S, Pandey P, Yamauchi T, Kumar S, Kaneki M, Kumar V, Bharti A, Yuan ZM, Ghanem L, Rana A, Weichselbaum R, Johnson G, Kufe D.
    Mol Cell Biol; 2000 Jul 31; 20(14):4979-89. PubMed ID: 10866655
    [Abstract] [Full Text] [Related]

  • 13. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage.
    Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JY.
    Nature; 1999 Jun 24; 399(6738):806-9. PubMed ID: 10391249
    [Abstract] [Full Text] [Related]

  • 14. Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms.
    Pandey P, Raingeaud J, Kaneki M, Weichselbaum R, Davis RJ, Kufe D, Kharbanda S.
    J Biol Chem; 1996 Sep 27; 271(39):23775-9. PubMed ID: 8798604
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor.
    Sutherland CL, Heath AW, Pelech SL, Young PR, Gold MR.
    J Immunol; 1996 Oct 15; 157(8):3381-90. PubMed ID: 8871635
    [Abstract] [Full Text] [Related]

  • 17. Impaired jun-NH2-terminal kinase activation by ultraviolet irradiation in fibroblasts of patients with Cockayne syndrome complementation group B.
    Dhar V, Adler V, Lehmann A, Ronai Z.
    Cell Growth Differ; 1996 Jun 15; 7(6):841-6. PubMed ID: 8780897
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.
    Vasilevskaya IA, Rakitina TV, O'Dwyer PJ.
    Mol Pharmacol; 2004 Jan 15; 65(1):235-43. PubMed ID: 14722256
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.